Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 10/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL28763 | 1.00 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 1.00 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29278843 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1375329 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29279662 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4203942-B1 | IBRUTINIB FOR USE IN TREATING COCAINE USE DISORDER AND RELATED CONDITIONS | UNIV EMORY (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3713986-B1 | COMPOSITION | REBIO TECH OY (FI) | 2026-04-01 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4615820-B1 | CRYSTALLINE FORMS OF EVENAMIDE | NEWRON PHARM SPA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4076461-B1 | LUMATEPERONE FOR USE IN SCHIZOPHRENIA TREATMENT | INTRA CELLULAR THERAPIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4049681-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3258950-B1 | ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE | AMYLONIX AB (SE) | 2025-10-29 | — | — | EP | claimed |
| WO-2023014211-A1 | ADVERTISEMENT-BASED SYSTEM AND METHOD FOR PROMOTING MOBILITY AND LOGISTICS SERVICES | DOPLLER, S DE RL DE CV (MX) | 2023-02-09 | — | — | WO | claimed |
| US-11471406-B2 | Oral film formulation for modulating absorption profile | INTELGENX CORP. (CA) | 2022-10-18 | — | — | US | claimed |
| WO-2022195044-A1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-09-22 | — | — | WO | claimed |
| WO-2022170411-A1 | MULTI-CREDIT PLATFORM INCLUDING PAYMENT IN INSTALMENTS FOR MISCELLANEOUS CASH PAYMENTS VIA PIX WITH VIRTUAL CARD | PIXCARD PLATAFORMA DE INOVACOES FINANCEIRAS LTDA (BR) | 2022-08-18 | — | — | WO | claimed |
| EP-3544599-B1 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | INST NAT SANTE RECH MED (FR) | 2022-08-17 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| EP-3723737-B1 | POROUS SILICA PARTICLES FOR USE IN COMPRESSED PHARMACEUTICAL DOSAGE FORM | NANOLOGICA AB (SE) | 2022-05-18 | — | — | EP | claimed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3586828-B1 | METHOD FOR PREPARING BIODEGRADABLE MICROSPHERES HAVING IMPROVED STABILITY AND STORAGE STABILITY | G2GBIO INC (KR) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | TAS2R42, TAS2R39, TAS2R45 | DRD2 2866/4885HTR2A 972/4885HTR2C 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.